Trial Profile
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2017
Price :
$35
*
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Alios BioPharma
- 03 Jan 2017 Status changed from not yet recruiting to completed.
- 15 Feb 2016 New trial record